AngioDynamics, Inc. ANGO
12.25 USD +0.52 (+4.43%)
At closeNov 4, 2026, 4:01 PM EST
12.25 0.00 0.00%
After hours · Nov 4, 4:01 PM ET
12.02 Day range 12.73
9.39 52-week range 16.29
- YTD
- -4.60%
- 1 year
- +2.60%
News
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com AngioDynamics Reports DIRECT Study Findings Showing Longer Overall Survival In Stage III Pancreatic Ductal Adenocarcinoma, Gets Category I CPT Code For Open IRE Ablation Of Pancreatic Tumors, Effective January 1, 2027 Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic…
businesswire.com AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
seekingalpha.com AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction,…
gurufocus.com AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste
businesswire.com AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
benzinga.com HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18 HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $19 to $18.
zacks.com ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
benzinga.com AngioDynamics Stock Is Falling Thursday: What's Going On? AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results.
benzinga.com AngioDynamics Stock Is Falling Thursday: What's Going On? ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.
benzinga.com Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
seekingalpha.com AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
fool.com Why AngioDynamics Crashed Today AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.
marketbeat.com AngioDynamics Q1 Earnings Call Highlights AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year…
benzinga.com AngioDynamics Q1 2027 Earnings Call: Complete Transcript AngioDynamics (NASDAQ:ANGO) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to…
zacks.com AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
defenseworld.net AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance AngioDynamics (NASDAQ: ANGO - Get Free Report) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of -0.290-0.240 for the period, compared to the…
benzinga.com Earnings Scheduled For October 8, 2026 Companies Reporting Before The Bell • Tilray Brands (NASDAQ:TLRY) is likely to report quarterly loss at $0.15 per share on revenue of $266.42 million. • Helen Of Troy (NASDAQ:HELE) is projected to…
benzinga.com AngioDynamics Appoints Eric Honroth As President And CEO, Effective November 2 Mr. Honroth will succeed Jim Clemmer, who will depart the Board on November 2, 2026, and will remain in a consulting capacity to ensure a smooth transition.The appointment follows a Board-led search…
benzinga.com AngioDynamics Affirms FY2027 Adj EPS Guidance of $(0.29)-$(0.24) vs $(0.27) Est; Affirms FY2027 Sales Guidance of $336.000M-$341.000M vs $337.400M Est AngioDynamics (NASDAQ:ANGO) affirms FY2027 Adj EPS guidance from $(0.29)-$(0.24) to $(0.29)-$(0.24) vs $(0.27) analyst estimate. Affirms FY2027 sales outlook from $336.000 million-$341.000 million to…
benzinga.com AngioDynamics Q1 Adj. EPS $(0.04) Beats $(0.11) Estimate, Sales $80.915M Beat $80.500M Estimate AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. This is a 60 percent increase over losses of $(0.10)…
businesswire.com AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
businesswire.com AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system,…
businesswire.com AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment…
businesswire.com AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment…
defenseworld.net 32,900 Shares in AngioDynamics, Inc. $ANGO Acquired by Canada Pension Plan Investment Board Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with…
defenseworld.net AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the…
zacks.com AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue? AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
marketbeat.com AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and…
zacks.com Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure? AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.- benzinga.com HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19 HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $19.
- benzinga.com Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20 Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $20.
- benzinga.com Full Transcript: AngioDynamics Q4 2026 Earnings Call AngioDynamics (NASDAQ:ANGO) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
- benzinga.com Earnings Scheduled For July 14, 2026 Companies Reporting Before The Bell • Grupo Aeroportuario del (NYSE:PAC) is likely to report quarterly earnings at $3.25 per share on revenue of $862.92 million. • JPMorgan Chase (NYSE:JPM) is…
- benzinga.com AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs $329.600M Est AngioDynamics (NASDAQ:ANGO) is looking for FY2027 Adj EPS of $(0.29)-$(0.24) vs $(0.16) analyst estimate. sees sales of $336.000 million-$341.000 million vs $329.600 million analyst estimate.
benzinga.com AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M Estimate AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 133.33 percent decrease over losses of…- benzinga.com AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality…
benzinga.com Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock jumped 11.73%.- benzinga.com AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate Cancer Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 monthsResults Presented at AUA 2026AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring…
benzinga.com Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16 Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.- benzinga.com Earnings Scheduled For April 2, 2026
- benzinga.com AngioDynamics Raises FY2026 Adj EPS Guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) Est; Raises FY2026 Sales Guidance from $312.000M-$314.000M to $313.500M-$315.500M vs $312.881M Est AngioDynamics (NASDAQ:ANGO) raises FY2026 Adj EPS guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) analyst estimate. Raises FY2026 sales outlook from $312.000 million-$314.000 million to…
- benzinga.com AngioDynamics Q3 Adj. EPS $(0.07) Beats $(0.11) Estimate, Sales $78.423M Beat $76.767M Estimate AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 12.5 percent increase over losses of…
benzinga.com Nasdaq Gains Over 1% On War De-Escalation Hopes: Investor Fear Eases, But Fear & Greed Index Remains In 'Extreme Fear' Zone Stocks end higher, Fear & Greed Index eases, Trump suggests quick military withdrawal from Iran, earnings disappoint for RH and Nike.
benzinga.com Acuity, Lindsay And 3 Stocks To Watch Heading Into Thursday U.S. stock futures trading lower, Acuity and Visionary Holdings report strong earnings, Lindsay Corp expected to post earnings, Globalstar shares jump after Amazon acquisition talks, AngioDynamics…- benzinga.com AngioDynamics Expands European Indications For NanoKnife System To Include Soft Tissue Ablation For Tumors Of Liver, Pancreas, Kidney, And Prostate Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor TypesAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative…
benzinga.com Dow Jumps Over 400 Points; US Services Activity Falls In December 
benzinga.com US Stocks Mixed; Nasdaq Gains Over 50 Points - benzinga.com Earnings Scheduled For January 6, 2026